Blog
Featured post
Truveta Data leads a new era in cancer research
With more than 7 million oncology patient journeys spanning more than 100 cancer types, Truveta delivers an unprecedented breadth of regulatory grade data to support researchers in accelerating oncology therapy adoption and advancing critical cancer research.
Shifting trends in initiation of disease-modifying therapies for multiple sclerosis
The proportion of patients initiating treatment for multiple sclerosis (MS) with a high efficacy disease-modifying therapy (DMT) more than doubled from 2018 to 2025, reflecting...
New AAP guidelines are changing pediatric obesity treatment—but there’s still work to do
In 2023, the American Academy of Pediatrics (AAP) released groundbreaking new guidelines recommending early treatment for childhood and adolescent obesity—including the use of...
Truveta Experts: Treatment trends for trigeminal neuralgia
This post kicks off our new series, Truveta Experts— a spotlight on the data scientists, researchers, clinicians, and analysts working behind the scenes to drive healthcare...
Real-world survival outcomes for CRT and CCM therapies align with landmark trials
A new peer-reviewed study from researchers at Saint Luke’s Mid America Heart Institute, Impulse Dynamics, and the Cardiovascular Research Foundation demonstrates the power of...
Understanding the potential impact of the upcoming ACIP vote on thimerosal-containing influenza vaccines
Thimerosal is a preservative contained in some vaccines, which has been used and considered safe for decades. During the June 2025 ACIP meeting, a presentation and vote on the...
Biosimilar use is on the rise – but 1 in 8 patients return to Humira
Switching from bio-originator Humira to a biosimilar peaked in April 2024 - the month an important formulary change took effect - and remains higher than 2023, suggesting growing...
The first FDA-approved Alzheimer’s blood test — and the power of real-world data to measure its impact
In May 2025, the FDA cleared the first blood test to aid in diagnosing Alzheimer’s disease, making early detection more accessible than ever. The Lumipulse test measures...
New study finds GLP-1 RA medications may significantly reduce risk of alcohol-related hospitalization
Truveta and collaborators partnered on a new large-scale study that considers the potential benefits of GLP-1 RA for AUD, among those with diabetes and/or obesity. Using a target...
Understanding the impact of the COVID-19 pandemic on childhood MMR vaccination patterns
Timely receipt of the MMR vaccine for children has been declining since 2021, with just 76.9% of children receiving the MMR vaccine in 2024 on time. The odds of non-vaccination...